BlackRock’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

BlackRock’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-6,006	Closed	-$3K	–	3899
2016 Q3	$3K	Buy	+6,006	New	+$2.75K	﹤0.01%	3593
2016 Q2	–	Sell	-1,826	Closed	-$3K	–	3959
2016 Q1	$3K	Buy	1,826 +712	+64%	+$1.41K	﹤0.01%	3437
2015 Q4	$4K	Hold	1,114	–	–	﹤0.01%	3244
2015 Q3	$7K	Hold	1,114	–	–	﹤0.01%	2925
2015 Q2	$11K	Hold	1,114	–	–	﹤0.01%	2770
2015 Q1	$8K	Buy	1,114 +196	+21%	+$1.32K	﹤0.01%	2898
2014 Q4	$5K	Hold	918	–	–	﹤0.01%	3100
2014 Q3	$5K	Hold	918	–	–	﹤0.01%	3116
2014 Q2	$6K	Buy	918 +859	+1,456%	+$5.47K	﹤0.01%	3110
2014 Q1	$0	Buy	+59	New	+$350	﹤0.01%	3248

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

BlackRock's NWBO Position: Q4 2016 in Review

BlackRock sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 6,006 shares — an estimated $3K sold.

BlackRock first reported a position in NWBO in Q1 2014 and held it in 10 quarters. The position peaked at $11K in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

BlackRock reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
BlackRock sold 6,006 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $3K.
BlackRock first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 10 quarters.
BlackRock's Northwest Biotherapeutics, Inc. Common stock position peaked at $11K in Q2 2015.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on BlackRock's 13F filing for Q4 2016, filed 10 Feb 2017.